ALLOUS
After Hours
Back To Top
Last Updated: Nov 12, 2019 4:33 p.m. EST Delayed quote

$27.98

1.31 4.91%
After Hours Volume: 1.4K
Health Care/Life Sciences -0.06%
Close Chg Chg %
$26.67 -0.49 -1.80% -0.49 -1.80%
Advanced Charting
  • $
  • %
  • Vol
Advanced Charting
78.35% vs Avg.
Volume: 294.8K 65 Day Avg. - 376.3K
Open: 26.31
Close: 26.67
26.25 Day Low/High 27.56
Day Range
23.37 52 Week Low/High 33.96

Your Watchlist

Customize MarketWatch

Have Watchlists? Log in to see them here or sign up to get started.

Symbol
Company
Price
Chg/Chg %
No Items in Watchlist

There are currently no items in this Watchlist.

No Saved Watchlists

Create a list of the investments you want to track.

Uh oh

Something went wrong while loading Watchlist.

Recently Viewed Tickers

No Recent Tickers

Visit a quote page and your recently viewed tickers will be displayed here.

Key Data

  • Open $26.31
  • Day Range 26.25 - 27.56
  • 52 Week Range 23.37 - 33.96
  • Market Cap $3.31B
  • Shares Outstanding 121.54M
  • Public Float 47.23M
  • Beta 1.30
  • Rev. per Employee n/a
  • P/E Ratio n/a
  • EPS $-1.61
  • Yield n/a
  • Dividend n/a
  • Ex-Dividend Date n/a
  • Short Interest 12.41M 10/31/19
  • % of Float Shorted 26.28%
  • Average Volume 376.3K

Performance

5 Day
  • 3.01%
1 Month
  • 1.14%
3 Month
  • -3.47%
YTD
  • -0.97%
1 Year
  • 6.66%

Recent News

  • MarketWatch
  • WSJ

Senator Dianne Feinstein’s Husband Sold Nvidia Stock, Bought FireEye

Allogene Therapeutics started at hold with $27 stock price target at Stifel Nicolaus

Allogene Therapeutics started at outperform with $45 stock price target at Oppenheimer

Allogene Therapeutics started at outperform with $40 stock price target at Raymond James

Allogene started at neutral with $29 stock price target at J.P. Morgan

Read full story

Hilton is considering options, including spinoffs and a possible sale

Read full story

Pinterest, Zoom Shares Surge in Trading Debuts

on The Wall Street Journal
Read full story

Zoom Opens 81% Higher in Trading Debut

on The Wall Street Journal
Read full story

Biotechs With No Drugs in Trial Are Raising Millions in IPOs

on The Wall Street Journal

Recent News

  • Other News
  • Press Releases

Allogene Moves Forward With CAR-T Therapy Pipeline

Allogene Moves Forward With CAR-T Therapy Pipeline

on Seeking Alpha

10-Q: ALLOGENE THERAPEUTICS, INC.

10-Q: ALLOGENE THERAPEUTICS, INC.

on Edgar Online - (EDG = 10Q, 10K)

Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q3 2019 Results - Earnings Call Transcript

Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q3 2019 Results - Earnings Call Transcript

on Seeking Alpha

Allogene teams up with Notch to develop next-gen CAR T therapies

Allogene teams up with Notch to develop next-gen CAR T therapies

on Seeking Alpha

Sell-siders like BioNTech in premarket analyst action

Sell-siders like BioNTech in premarket analyst action

on Seeking Alpha

Allogene Therapeutics: Stay On The Sidelines On This Until 2020

Allogene Therapeutics: Stay On The Sidelines On This Until 2020

on Seeking Alpha

Crispr Therapeutics: At The Top Of My Shopping List

Crispr Therapeutics: At The Top Of My Shopping List

on Seeking Alpha

J.P. Morgan Keeps a Hold Rating on Allogene Therapeutics Inc (ALLO)

In a report released yesterday, Cory Kasimov from J.P.[...]

on SmarterAnalyst

Allogene Therapeutics Inc (ALLO) Gets a Buy Rating from William Blair

In a report released today, Raju Prasad from William Blair maintained a Buy rating on Allogene Therapeutics Inc (ALLO). The company’s shares closed ...[...]

on SmarterAnalyst

Moderna, Allogene Have Disappointed Investors

Moderna, Allogene Have Disappointed Investors

on GuruFocus.com

Allogene to work with Stanford on research into nucleic acid delivery system

Allogene to work with Stanford on research into nucleic acid delivery system

on Seeking Alpha

Allogene Therapeutics (ALLO) Investor Presentation - Slideshow

Allogene Therapeutics (ALLO) Investor Presentation - Slideshow

on Seeking Alpha

Apple, IPOs And German Auto (Stocks To Watch Podcast)

Apple, IPOs And German Auto (Stocks To Watch Podcast)

on Seeking Alpha

Stocks To Watch: Apple, IPOs And German Auto

Stocks To Watch: Apple, IPOs And German Auto

on Seeking Alpha

Genomic Medicine: Fall 2019 Tracking Update

Genomic Medicine: Fall 2019 Tracking Update

on Seeking Alpha

10-Q: ALLOGENE THERAPEUTICS, INC.

on Edgar Online - (EDG = 10Q, 10K)

Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q2 2019 Results - Earnings Call Transcript

on Seeking Alpha

Biotech Stocks Getting Ready To Explode

on Seeking Alpha

Wall Street Brunch

on Seeking Alpha

Spotlight On FOMC, Slack And Paris Air Show (Stocks To Watch Podcast)

on Seeking Alpha

Allogene Therapeutics Announces Year-End 2019 Media Event and Investor Conference Schedule

Allogene Therapeutics Announces Year-End 2019 Media Event and Investor Conference Schedule

on GlobeNewswire

Allogene Therapeutics Announces Year-End 2019 Media Event and Investor Conference Schedule

Allogene Therapeutics Announces Year-End 2019 Media Event and Investor Conference Schedule

on GlobeNewswire

Allogene Therapeutics Announces Pre-Clinical Data Presentations Supporting AlloCAR T(TM) Pipeline at 61st American Society of Hematology Annual Meeting

Allogene Therapeutics Announces Pre-Clinical Data Presentations Supporting AlloCAR T(TM) Pipeline at 61st American Society of Hematology Annual Meeting

on GlobeNewswire

Allogene Therapeutics Announces Pre-Clinical Data Presentations Supporting AlloCAR T(TM) Pipeline at 61st American Society of Hematology Annual Meeting

Allogene Therapeutics Announces Pre-Clinical Data Presentations Supporting AlloCAR T(TM) Pipeline at 61st American Society of Hematology Annual Meeting

on GlobeNewswire

Allogene Therapeutics Reports Third Quarter 2019 Financial Results

Allogene Therapeutics Reports Third Quarter 2019 Financial Results

on GlobeNewswire

Allogene Therapeutics Reports Third Quarter 2019 Financial Results

Allogene Therapeutics Reports Third Quarter 2019 Financial Results

on GlobeNewswire

Allogene Therapeutics and Notch Therapeutics Announce Collaboration to Research and Develop Induced Pluripotent Stem Cell (iPSC)-Derived Allogeneic Therapies for Hematologic Cancer Indications

Allogene Therapeutics and Notch Therapeutics Announce Collaboration to Research and Develop Induced Pluripotent Stem Cell (iPSC)-Derived Allogeneic Therapies for Hematologic Cancer Indications

on GlobeNewswire

Allogene Therapeutics and Notch Therapeutics Announce Collaboration to Research and Develop Induced Pluripotent Stem Cell (iPSC)-Derived Allogeneic Therapies for Hematologic Cancer Indications

Allogene Therapeutics and Notch Therapeutics Announce Collaboration to Research and Develop Induced Pluripotent Stem Cell (iPSC)-Derived Allogeneic Therapies for Hematologic Cancer Indications

on GlobeNewswire

Allogene Therapeutics to Report Third Quarter 2019 Financial Results on November 5, 2019

Allogene Therapeutics to Report Third Quarter 2019 Financial Results on November 5, 2019

on GlobeNewswire

Allogene Therapeutics to Report Third Quarter 2019 Financial Results on November 5, 2019

Allogene Therapeutics to Report Third Quarter 2019 Financial Results on November 5, 2019

on GlobeNewswire

Allogene Therapeutics Enters Research Collaboration Directed at Enhancing Future Cancer Immunotherapies

Allogene Therapeutics Enters Research Collaboration Directed at Enhancing Future Cancer Immunotherapies

on GlobeNewswire

Allogene Therapeutics Enters Research Collaboration Directed at Enhancing Future Cancer Immunotherapies

Allogene Therapeutics Enters Research Collaboration Directed at Enhancing Future Cancer Immunotherapies

on GlobeNewswire

Allogene Therapeutics Announces September 2019 Investor Conference Schedule

Allogene Therapeutics Announces September 2019 Investor Conference Schedule

on GlobeNewswire

Allogene Therapeutics Announces September 2019 Investor Conference Schedule

Allogene Therapeutics Announces September 2019 Investor Conference Schedule

on GlobeNewswire

Allogene Therapeutics Reports Second Quarter 2019 Financial Results

on GlobeNewswire

Allogene Therapeutics Reports Second Quarter 2019 Financial Results

on GlobeNewswire

Allogene Therapeutics Appoints Rafael G. Amado, M.D. as Executive Vice President of Research and Development and Chief Medical Officer

on GlobeNewswire

Allogene Therapeutics Appoints Rafael G. Amado, M.D. as Executive Vice President of Research and Development and Chief Medical Officer

on GlobeNewswire

Vida Ventures Closes $600 Million Vida II Fund to Support Life Science Innovation

on BusinessWire - BZX

Allogene Therapeutics to Report Second Quarter 2019 Financial Results on August 7, 2019

on GlobeNewswire

Allogene Therapeutics Inc.

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, and Joshua A. Kazam on November 2017 and is headquartered in South San Francisco, CA. (See Full Profile)

Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 13 Full Ratings